Skip to main content
Top
Published in: Diabetologia 11/2017

Open Access 01-11-2017 | Article

Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Authors: Rebecca K. Simmons, Simon J. Griffin, Torsten Lauritzen, Annelli Sandbæk

Published in: Diabetologia | Issue 11/2017

Login to get access

Abstract

Aims/hypothesis

There is continuing debate about the net benefits of population screening for type 2 diabetes. We compared the risk of cardiovascular disease (CVD) and mortality among incident cases of type 2 diabetes in a screened group with those in an unscreened group.

Methods

In this register-based non-randomised controlled trial, eligible individuals were all men and women aged 40–69 years without known diabetes, registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes-risk-score questionnaire. Individuals at moderate-to-high risk were invited to visit their family doctor for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other practices in Denmark constituted the retrospectively constructed no-screening (control) group. In this post hoc analysis, we identified individuals from the screening and no-screening groups who were diagnosed with diabetes between 2001 and 2009 (n = 139,075), and compared risk of CVD and mortality in these groups between 2001 and 2012.

Results

In the screening group, 27,177/153,107 (18%) individuals attended for screening, of whom 1533 were diagnosed with diabetes. Between 2001 and 2009, 13,992 people were newly diagnosed with diabetes in the screening group (including those diagnosed by screening) and 125,083 in the no-screening group. Between 2001 and 2012, the risks of CVD and mortality were lower among individuals with diabetes in the screening group compared with individuals with diabetes in the no-screening (control) group (CVD HR 0.84, 95% CI 0.80, 0.89; mortality HR 0.79, 95% CI 0.74, 0.84).

Conclusions/interpretation

A single round of diabetes screening and cardiovascular risk assessment in middle-aged Danish adults in general practice was associated with a significant reduction in risk of all-cause mortality and CVD events in those diagnosed with diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kuo HS, Chang HJ, Chou P, Teng L, Chen TH (1999) A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 28:233–240CrossRefPubMed Kuo HS, Chang HJ, Chou P, Teng L, Chen TH (1999) A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 28:233–240CrossRefPubMed
2.
go back to reference Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH (2000) Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 31:396–402CrossRefPubMed Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH (2000) Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 31:396–402CrossRefPubMed
3.
go back to reference Kahn R, Alperin P, Eddy D et al (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365–1374CrossRefPubMed Kahn R, Alperin P, Eddy D et al (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365–1374CrossRefPubMed
4.
5.
go back to reference Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 38:1449–1455CrossRefPubMedPubMedCentral Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 38:1449–1455CrossRefPubMedPubMedCentral
6.
go back to reference Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S (2007) Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335:486CrossRefPubMedPubMedCentral Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S (2007) Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335:486CrossRefPubMedPubMedCentral
7.
go back to reference Adriaanse MC, Snoek FJ (2006) The psychological impact of screening for type 2 diabetes. Diabetes Metab Res Rev 22:20–25CrossRefPubMed Adriaanse MC, Snoek FJ (2006) The psychological impact of screening for type 2 diabetes. Diabetes Metab Res Rev 22:20–25CrossRefPubMed
8.
go back to reference Department of Health (2008) Putting prevention first. Vascular checks: risk assessment and management. Department of Health, London Department of Health (2008) Putting prevention first. Vascular checks: risk assessment and management. Department of Health, London
9.
go back to reference Siu AL (2015) Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. preventive services task force recommendation statement. Ann Intern Med 163:861–868CrossRefPubMed Siu AL (2015) Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. preventive services task force recommendation statement. Ann Intern Med 163:861–868CrossRefPubMed
10.
go back to reference Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748CrossRefPubMedPubMedCentral Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748CrossRefPubMedPubMedCentral
11.
go back to reference Simmons RK, Griffin, S.J., Witte, D.R., Borch-Johnsen, K., Lauritzen, T., Sandbæk, A. (2016) Effect of population screening for cardiovascular risk factors and type 2 diabetes on mortality and cardiovascular events among 1,912,392 Danish adults. Diabetologia DOI:10.1007/s00125-017-4323-2 Simmons RK, Griffin, S.J., Witte, D.R., Borch-Johnsen, K., Lauritzen, T., Sandbæk, A. (2016) Effect of population screening for cardiovascular risk factors and type 2 diabetes on mortality and cardiovascular events among 1,912,392 Danish adults. Diabetologia DOI:10.​1007/​s00125-017-4323-2
12.
go back to reference Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167CrossRefPubMedPubMedCentral Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167CrossRefPubMedPubMedCentral
13.
go back to reference Engelgau MM, Narayan KM, Herman WH (2000) Screening for type 2 diabetes. Diabetes Care 23:1563–1580CrossRefPubMed Engelgau MM, Narayan KM, Herman WH (2000) Screening for type 2 diabetes. Diabetes Care 23:1563–1580CrossRefPubMed
14.
go back to reference Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24(Suppl 3):S6–11CrossRefPubMed Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24(Suppl 3):S6–11CrossRefPubMed
15.
go back to reference Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573CrossRefPubMed Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573CrossRefPubMed
16.
go back to reference Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733CrossRefPubMed Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733CrossRefPubMed
17.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003CrossRefPubMed Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003CrossRefPubMed
18.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553CrossRefPubMed Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553CrossRefPubMed
19.
go back to reference Green A, Sortso C, Jensen PB, Emneus M (2015) Validation of the Danish national diabetes register. Clin Epidemiol 7:5–15PubMed Green A, Sortso C, Jensen PB, Emneus M (2015) Validation of the Danish national diabetes register. Clin Epidemiol 7:5–15PubMed
21.
go back to reference Huber PJ (1967) The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, Berkeley, pp 221–233 Huber PJ (1967) The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, Berkeley, pp 221–233
22.
go back to reference Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815–819CrossRefPubMed Harris MI, Klein R, Welborn TA, Knuiman MW (1992) Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15:815–819CrossRefPubMed
23.
go back to reference Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ (2011) How much does screening bring forward the diagnosis of diabetes and reduce complications? 12-year follow-up of the Ely cohort. Diabetologia 55:1651–1659CrossRef Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ (2011) How much does screening bring forward the diagnosis of diabetes and reduce complications? 12-year follow-up of the Ely cohort. Diabetologia 55:1651–1659CrossRef
24.
go back to reference Porta M, Curletto G, Cipullo D et al (2014) Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care 37:1668–1674CrossRefPubMed Porta M, Curletto G, Cipullo D et al (2014) Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care 37:1668–1674CrossRefPubMed
26.
27.
go back to reference Prasad V, Lenzer J, Newman DH (2016) Why cancer screening has never been shown to “save lives”-and what we can do about it. BMJ 352:h6080CrossRefPubMed Prasad V, Lenzer J, Newman DH (2016) Why cancer screening has never been shown to “save lives”-and what we can do about it. BMJ 352:h6080CrossRefPubMed
28.
go back to reference Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K (2008) The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51:2187–2196CrossRefPubMed Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K (2008) The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51:2187–2196CrossRefPubMed
Metadata
Title
Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009
Authors
Rebecca K. Simmons
Simon J. Griffin
Torsten Lauritzen
Annelli Sandbæk
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4299-y

Other articles of this Issue 11/2017

Diabetologia 11/2017 Go to the issue